NCT07132242Not yet recruitingPhase 2
SHR-A1811 Combine With Pyrotinib for Locally Advanced/Metastatic HER2 Positive Breast Cancer
Safety and Efficacy of SHR-A1811 Combine With Pyrotinib for the Treatment of HER2 Positive Locally Advanced or Metastatic Breast Cancer, a Phase II Study
Source: ClinicalTrials.gov · Last updated 20 Aug 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The goal of this clinical trial is to learn if SHR-A1811 combine with Pyrotinib is safe and tolerable for patients with HER2 positive breast cancer. It will also learn about the anti-tumor efficacy of this combination therapy. Participants will take SHR-A1811 and pyrotinib every three weeks, until disease progression or intolerable toxicity.
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 84 (estimated)
- First submitted
- 1 Aug 2025
- Start date
- 30 Aug 2025
- Primary completion date
- 30 Aug 2028
- Lead sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Diseases
- Metastatic breast cancer
- NCT number
- NCT07132242
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 84
- From 30 Aug 2025 to the primary completion date, 30 Aug 2028
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Prior Pyrotinib in Advanced/Metastatic Setting;
- Prior Tropoisomerase I Inhibitor ADC Therapy;
- Recent Major Surgery/Trauma;
- Inability to swallow oral medication, chronic diarrhea, intestinal obstruction, or other factors significantly affecting drug ingestion or absorption;
- Known hypersensitivity to any component of the investigational drugs in this study protocol;
- Immunodeficiency/Organ Transplant;
- Severe concomitant illness or comorbid conditions that may interfere with planned treatment or preclude study participation, as assessed by the investigator. This includes, but is not limited to, active hepatitis B or pulmonary infection requiring treatment.
Other illness
- Other Malignancy;
- Interstitial Lung Disease (ILD)/Severe Pulmonary Conditions;
- Significant Cardiac Disease;
Other
- Active CNS Metastases;
- Uncontrolled Third-Space Fluid Accumulation;
- Pregnancy/Breastfeeding/Contraception;
Who the study is looking for
- Age: ≥18 years old and ≤70 years old;
- Pathologically confirmed HER2-positive locally advanced or metastatic breast cancer;
- Progression during or after prior HER2-targeted therapy and chemotherapy in the advanced/metastatic setting OR progression during/within 12 months after completion of trastuzumab and taxane-based chemotherapy in the neoadjuvant/adjuvant setting OR after 2 cycles of trastuzumab and taxane-based chemotherapy in the neoadjuvant setting with suboptimal response (assessed as non-response) for locally advanced disease;
- At least one measurable lesion per RECIST v1.1 criteria.
- ECOG performance status of 0 or 1.
- Adequate Organ Function
- Female subjects of childbearing potential must have a negative serum pregnancy test within 7 days before the first dose. Male subjects with partners of childbearing potential must be surgically sterile or agree to use effective contraception during the trial. Sperm donation is not permitted during the study period.
- Subjects must voluntarily enroll in this study, sign the informed consent form, demonstrate good compliance, and be willing to cooperate with follow-up.
Age in the registry: 18 years to 70 years · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.